<DOC>
	<DOCNO>NCT02194686</DOCNO>
	<brief_summary>1 . The number function circulate endothelial progenitor cell ( EPCs ) inversely associate coronary risk factor atherosclerotic disease . 2 . This double-blind , randomize , placebo-controlled trial evaluate effect cilostazol human early EPCs endothelial function well potential mechanism action patient high risk cardiovascular disease .</brief_summary>
	<brief_title>Effect Cilostazol Endothelial Progenitor Cells Endothelial Function High Risk Cardiovascular Disease</brief_title>
	<detailed_description>1. titration drug 1. run-in period : eligible subject screen baseline blood sample obtain 2. study period : 12 week - subject cilostazol subject dummy placebo - On first day end study period , follow-up data obtain procedure 3. blood sample measurement serum biomarkers - obtain peripheral vein study subject run-in period end treatment period study - sent isolation , cell culture , assay human EPCs - also store enzyme-linked immunosorbent assay ( stromal cell derive factor-alfa1 , adiponectin , soluble thrombomodulin , vascular endothelial growth factor ) 2. assay human EPCs 1. colony formation EPCs 2. quantification EPCs apoptotic endothelial cell 3. chemotactic motility , proliferation/viability apoptosis assay 3. measurement flow-mediated dilatation ( FMD ) leave brachial artery sonography</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>highrisk patient least one follow situation without preexist cardiovascular disease include peripheral artery disease coronary artery disease : type 2 diabetes mellitus metabolic syndrome stage 3 ( advance ) chronic kidney disease 2 coronary risk factor ( male &gt; 45 year female &gt; 55 year , hypertension , tobacco smoking , hyperlipidemia , family history cardiovascular disease ) anklebrachial index less 0.9 1.3 one leg significant stenosis ( 50 % compare reference vessel ) peripheral artery image study symptom suggest peripheral artery disease least one leg clinical electrocardiographic evidence coronary artery disease clinical evidence cerebrovascular disease severe liver dysfunction ( transaminases &gt; 10 time upper normal limit , history liver cirrhosis , hepatoma ) leave ventricular ejection fraction ( &lt; 50 % echocardiography ) document active malignancy chronic inflammatory disease know drug allergy history cilostazol current use cilostazol cAMPelevator premenopausal woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>cilostazol</keyword>
	<keyword>progenitor cell</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>risk factor</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>biological marker</keyword>
	<keyword>endothelial function</keyword>
</DOC>